We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Intranasal Fentanyl at Reducing Pain During Abscess Incision and Drainage (I&D) in Children

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01549002
First Posted: March 8, 2012
Last Update Posted: August 28, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Daniel Sing-Kwong Tsze, Columbia University
Results First Submitted: February 2, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Single (Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Abscess
Pain
Interventions: Drug: Intranasal Fentanyl
Drug: Intravenous Morphine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Intranasal Fentanyl

Patients in this arm will receive intranasal Fentanyl (50 micrograms/mL) as their pre-I&D analgesic. The one time total dose to be used is 2 micrograms / kilogram, to a maximum of 100 micrograms. The medication will be delivered intranasally via an atomizer in 4 equally divided aliquots (2 per nare).

The abscess I&D will be followed according to protocol using topical and local anesthetic.

Intranasal Fentanyl: Drug: Fentanyl 50 micrograms/mL Dosage: 2 micrograms per kilogram (maximum 100 micrograms) Drug delivery: Intranasal via mucosal atomization device (MAD® Nasal, Wolfe Tory Medical Inc., Salt Lake City, UT) Frequency: one-time dose

Intravenous Morphine

Patients in this arm will receive intravenous morphine as their pre-I&D analgesic. The one time total dose to be used is 0.1 milligrams / kilogram, to a maximum of 8 milligrams. The medication will be delivered via slow IV push.

The abscess I&D will be followed according to protocol using topical and local anesthetic.

Intravenous Morphine: Drug: Morphine Dosage: 0.1 milligrams/kilogram (maximum 8 milligrams) Drug delivery: Slow IV push Frequency: one-time dose


Participant Flow:   Overall Study
    Intranasal Fentanyl   Intravenous Morphine
STARTED   10   10 
COMPLETED   10   6 
NOT COMPLETED   0   4 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Intranasal Fentanyl

Patients in this arm will receive intranasal Fentanyl (50 micrograms/mL) as their pre-I&D analgesic. The one time total dose to be used is 2 micrograms / kilogram, to a maximum of 100 micrograms. The medication will be delivered intranasally via an atomizer in 4 equally divided aliquots (2 per nare).

The abscess I&D will be followed according to protocol using topical and local anesthetic.

Intranasal Fentanyl: Drug: Fentanyl 50 micrograms/mL Dosage: 2 micrograms per kilogram (maximum 100 micrograms) Drug delivery: Intranasal via mucosal atomization device (MAD® Nasal, Wolfe Tory Medical Inc., Salt Lake City, UT) Frequency: one-time dose

Intravenous Morphine

Patients in this arm will receive intravenous morphine as their pre-I&D analgesic. The one time total dose to be used is 0.1 milligrams / kilogram, to a maximum of 8 milligrams. The medication will be delivered via slow IV push.

The abscess I&D will be followed according to protocol using topical and local anesthetic.

Intravenous Morphine: Drug: Morphine Dosage: 0.1 milligrams/kilogram (maximum 8 milligrams) Drug delivery: Slow IV push Frequency: one-time dose

Total Total of all reporting groups

Baseline Measures
   Intranasal Fentanyl   Intravenous Morphine   Total 
Overall Participants Analyzed 
[Units: Participants]
 10   10   20 
Age 
[Units: Years]
Median (Inter-Quartile Range)
 15.3 
 (12.2 to 17.4) 
 15.4 
 (10.2 to 16.4) 
 15.4 
 (11.8 to 16.8) 
Gender 
[Units: Participants]
     
Female   8   7   15 
Male   2   3   5 
Observational Scale of Behavioral Distress - revised [1] 
[Units: Units on a scale]
Mean (Standard Deviation)
 0  (0)   0  (0)   0  (0) 
[1] An observational scale of pain and distress during procedures. Scores can range from 0 to 23.5 units for each phase. A higher score indicates a greater degree of pain and distress. The total OSBD-R score is a summation of the OSBD-R score from each phase. For example, if there are six phases, the range of scores for OSBD-R is from 0 to 141. The measured baseline OSBD-R scores was ZERO for all patients.


  Outcome Measures

1.  Primary:   Score on the Observational Scale of Behavioral Distress Revised (OSBD-R)   [ Time Frame: Up to 10 minutes after the procedure completion ]

2.  Secondary:   Score on the Faces Pain Scale Revised (FPS-R)   [ Time Frame: Up to 10 minutes after procedure completion ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

3.  Secondary:   Score on Likert Scale for Patient Satisfaction   [ Time Frame: 10 minutes after procedure completion ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Daniel Fenster
Organization: ColumbiaU
phone: 212-305-9825
e-mail: dbf2114@columbia.edu



Responsible Party: Daniel Sing-Kwong Tsze, Columbia University
ClinicalTrials.gov Identifier: NCT01549002     History of Changes
Other Study ID Numbers: AAAI0699
First Submitted: February 2, 2012
First Posted: March 8, 2012
Results First Submitted: February 2, 2015
Results First Posted: August 21, 2015
Last Update Posted: August 28, 2015